Carlsmed, Inc. (CARL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Carlsmed, Inc. (CARL) has a cash flow conversion efficiency ratio of -0.087x as of June 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-7.36 Million) by net assets ($84.25 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see CARL company net worth for the company's overall valuation and market capitalisation.
Carlsmed, Inc. - Cash Flow Conversion Efficiency Trend (2023–2025)
This chart illustrates how Carlsmed, Inc.'s cash flow conversion efficiency has evolved over time, based on yearly financial data.
Carlsmed, Inc. Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Carlsmed, Inc. ranked by their cash flow conversion efficiency. See Carlsmed, Inc. cash debt coverage ratio to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Ozak Gayrimenkul Yatirim Ortakligi AS
IS:OZKGY
|
0.000x |
|
HANSEN TECHNOLOGIES LTD.
F:H2T
|
N/A |
|
Eik fasteignafélag hf
IC:EIK
|
0.017x |
|
Solusi Bangun Indonesia Tbk PT
JK:SMCB
|
0.014x |
|
TIDEWATER RENEWABLES LTD
F:7GZ
|
0.135x |
|
Qinhuangdao Tianqin Equipment Manufacturing Co.Ltd.
SHE:300922
|
-0.027x |
|
Chengdu Dahongli Machinery Co Ltd
SHE:300865
|
0.015x |
|
Cross Country Healthcare Inc
NASDAQ:CCRN
|
0.015x |
Annual Cash Flow Conversion Efficiency for Carlsmed, Inc. (2023–2025)
The table below shows the annual cash flow conversion efficiency of Carlsmed, Inc. from 2023 to 2025. View CARL share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $98.87 Million | $-28.98 Million | -0.293x | -181.29% |
| 2024-12-31 | $-70.63 Million | $-25.47 Million | 0.361x | -4.85% |
| 2023-12-31 | $-46.13 Million | $-17.48 Million | 0.379x | -- |
About Carlsmed, Inc.
Carlsmed, Inc., a commercial-stage medical technology company, designs, manufactures, and markets AI-enabled personalized spine surgery solutions. The company develops aprevo, a comprehensive technology platform for spine fusion surgery procedures. Its aprevo platform includes proprietary surgical planning software, using outcomes-based algorithms that are aided with artificial intelligence, and … Read more